Other genetic variants potentially implicated in NAFLD development and progression were neurocan (NCAN-rs2228603), protein phosphatase 1, regulatory (inhibitor) subunit 3B (PPP1R3B-rs4240624), glucokinase regulator (GCKR-rs780094), and lysophospholipase-like 1 (LYPLAL1-rs12137855) (51). The gene discussed is LYPLAL1; the disease is metabolic dysfunction-associated steatotic liver disease.